Akebia Therapeutics (AKBA) EBIT (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of EBIT data on file, last reported at -$4.7 million in Q1 2026.

• EBIT for Q1 2026 came in at -$4.7 million, down 134.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (up 124.02% YoY), and the FY2025 annual result was $23.5 million, up 146.56% from the prior year.
• EBIT climbed to -$4.7 million in Q1 2026 per AKBA's latest filing, from -$8.6 million in the prior quarter.
• Over five years, EBIT peaked at $34.1 million in Q2 2022 and troughed at -$59.6 million in Q1 2022.
• A 5-year average of -$9.3 million and a median of -$8.7 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2024 and 2025: EBIT plunged 1141.27% in 2024, then jumped 261.48% in 2025.
• A 5-year view of EBIT shows it stood at -$4.9 million in 2022, then soared by 128.22% to $1.4 million in 2023, then sank by 1141.27% to -$14.3 million in 2024, then soared by 40.22% to -$8.6 million in 2025, then jumped by 45.1% to -$4.7 million in 2026.
• Business Quant data shows AKBA's EBIT at -$4.7 million in Q1 2026, -$8.6 million in Q4 2025, and $4.4 million in Q3 2025.